CF
SLS icon

Cantor Fitzgerald’s SELLAS Life Sciences SLS Stock Holding History

Cantor Fitzgerald’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,750
Closed -$25K – 318
2024
Q1 		$25K Buy
+24,750
New +$20.8K 0.01% 200

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
EH
Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Cantor Fitzgerald's SLS Position: Q2 2024 in Review

Cantor Fitzgerald sold out of SELLAS Life Sciences (SLS) in Q2 2024, closing a stake of 24,750 shares — an estimated $25K sold.

Cantor Fitzgerald first reported a position in SLS in Q1 2024 and held it in 1 quarter. The position peaked at $25K in Q1 2024. 30 funds tracked by Wall St. Rank hold SLS as of Q2 2024.

  • Cantor Fitzgerald reported no remaining SELLAS Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 24,750 SELLAS Life Sciences shares in Q2 2024, an estimated $25K.
  • Cantor Fitzgerald first reported a position in SELLAS Life Sciences in Q1 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's SELLAS Life Sciences position peaked at $25K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2024.

Based on Cantor Fitzgerald's 13F filing for Q2 2024, filed 14 Aug 2024.